Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU OKs Bivalent COVID-19 Vaccines From Pfizer/BioNTech & Moderna

Executive Summary

The European Commission will shortly issue marketing authorizations for bivalent versions of Comirnaty and Spikevax targeting the Omicron BA.1 subvariant, after the European Medicines Agency recommended their approval for EU-wide use. Bivalent Spikevax has also been provisionally approved in Australia.

You may also be interested in...



Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times

How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.

Coronavirus Notebook: UK OKs Second Bivalent Vaccine, European Companies Warn On Joint Vaccine Procurement Plans

The Swiss medicines regulator has approved the bivalent version of Spikevax and given the green light to use of the Novavax COVID-19 vaccine in younger people.

EU Regulator Eyes Mid-September For Decision On Comirnaty BA.4/BA.5 Booster Approval

As regulators continue to process and approve applications for new kinds of COVID-19 booster vaccines, evidence is still awaited on the real-world benefits conferred by the latest variant-adapted products. The European Medicines Agency and the European Centre for Disease Prevention and Control plan to issue a joint statement on the use of adapted vaccines next week, and the EMA has OKd a booster version of the Novavax vaccine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel